Implantation of the Venus P-Valve™ in the Pulmonic Position in Patients With Native Outflow Tracts
- Conditions
- Pulmonary Regurgitation
- Interventions
- Procedure: trans catheter heart valve replacement
- Registration Number
- NCT02846753
- Lead Sponsor
- Venus MedTech (HangZhou) Inc.
- Brief Summary
A prospective, non-randomized multi-center clinical investigation of the Venus P-Valve™ for the treatment of pulmonary regurgitation with or without stenosis in patient with native outflow tracts.
- Detailed Description
This study evaluates the implantation of the Venus P-Valve™ for the treatment of patients with an incompetent pulmonic valve, which causes blood to flow back from the pulmonary artery into the right heart ventricle during pumping of the heart (pulmonary regurgitation). Patients with and without narrowing (stenosis) of the right ventricular outflow tract will be included. The purpose of this protocol is to assess the safety and performance of Venus P-Valve™ implantation.
Post-procedure, a clinical visit will be scheduled at 30 days, 6 month, 12 months, and annually thereafter to 3 years. Population: Patients≥12 years with a body weight of ≥30kg, with significant pulmonary regurgitation (≥3+) with or without right ventricular outflow tract (RVOT) stenosis (mean Doppler gradient ≥35mmHg) with native right ventricular outflow tracts.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 84
Candidates for this study must meet all of the following Inclusion criteria:
- Age: range from 12-70 years of age
- Weight must be "equal to" or exceed 30 kilograms
- Subject presents with evidence of moderate or severe (≥3+) pulmonary regurgitation by TTE
- Subject presents with >30% pulmonary regurgitation fraction as defined by cardiac MRI
- Subject is symptomatic from his/her pulmonary regurgitation or meets MRI criteria for intervention: right ventricular ejection fraction (RVEF) < 45%, pulmonary regurgitant fraction (PRRF) >30% and increased right ventricular end-diastolic volume (RVEDV) >150ml/m2
- Subject will comply with specified follow-up evaluations, including echocardiograms and MRI
- The subject or the subject's legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the ethics committee and regulatory authority if applicable of the respective clinical site
- The subject and the treating physician agree that the subject will return for all required post-procedure follow up visits
- Catheterization is determined to be feasible by the treating physician
Candidates will be excluded from the study if any of the following conditions are present:
- Active infection requiring current antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics)
- Severe chest wall deformity
- Leukopenia (WBC<3000 mm3)
- Acute or chronic anemia (Hb <90g/l)
- Platelet count <100,000 cells/mm3
- In the judgment of the investigator, percutaneous introduction and delivery of the valve is not feasible
- Need for emergency cardiac or vascular surgery, including pulmonary embolectomy, for any reason
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
- History of, or active, endocarditis, unless the endocarditis has been treated >6 months previous to the procedure
- History of or current intravenous drug abuse
- A known hypersensitivity to aspirin or heparin
- Currently participating in an investigational drug or another device study [Note: Trials requiring extended follow up for products that were investigational, but have since become commercially available, are not considered investigational devices.]
- Major or progressive non-cardiac disease resulting in a life expectancy of <1yr
- Obstruction of the central veins preventing advancement of the pulmonary bioprosthesis delivery system to the heart
- Positive urine or serum pregnancy test in female subjects of child-bearing potential
- Ileofemoral vessel characteristics that would preclude safe placement of 19 French (F), 22 F and 24 F introducer sheath
- Contraindication for cardiac magnetic resonance imaging or inability to cooperate with a cardiac magnetic resonance imaging exam
- Need for concomitant interventional procedures
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Implantation of Venus P-Valve™ trans catheter heart valve replacement Implantation of the Venus P-Valve™ in the pulmonic position in patients with native outflow tracts; trans catheter heart valve replacement.
- Primary Outcome Measures
Name Time Method Hemodynamic Performance of Venus P-Valve™ measured as the mean transvalvular pressure (mmHg) 1 month Hemodynamic performance, measured as the mean transvalvular pressure gradient measured by transthoracic echocardiogram at month-1
Performance of Venus P-Valve™ measured as percentage of subjects with structural valve deterioration month 6 Structural valve deterioration assessment includes stent fracture, leaflet mobility, thickening and calcification
Safety of Venus P-Valve™ measured as probability of Major Adverse Cardiac and Cerebro-vascular Event (MACCE) month 1 follow-up Occurrence of MACCE (defined as death, myocardial infarction, reoperation, vascular injury resulting in the need for an unplanned vascular grafting intervention, stroke, and pulmonary embolism) calculated as freedom-from-MACCE probability at month-1, calculated using the Kaplan Meier method
Performance of Venus P-Valve™ measured as change of pulmonary regurgitation (regurgitation classification by transthoracic echocardiogram) baseline, day 1, month 1, 6, 12 and annually thereafter to 3 years post procedure Improvement or abolition of pulmonary regurgitation assessed by transthoracic echocardiogram at baseline, day 1, month 1, 6, 12 and annually thereafter to 3 years post procedure, with grading of pulmonary stenosis defined as: mild \<2, moderate: 2-4; severe \>4
Safety of Venus P-Valve™ measured as probability of death/reoperation month 12 follow-up Occurrence of death or reoperation (Valve and/or procedure related) calculated as a composite freedom-of-death and -reoperation probability at 12 months. The acceptance criterion for mortality and reoperation is 16% (or equivalently 84% freedom from death and reoperation). If the lower 95% confidence limit for survival and freedom from reoperation at 12 months is greater than 84%, the acceptance criterion for safety will have been met.
Performance of Venus P-Valve™ measured as Success rate of valve placement and implantation up to 30 days The device success is defined as the percentage of subjects with successful implant of the P-Valve assessed at the earliest evaluable echocardiogram. Linearized rates will be presented.
Performance of Venus P-Valve™ measured as change of pulmonary regurgitation (regurgitation classification by MRI) baseline and month 6 Improvement or abolition of pulmonary regurgitation assessed by MRI at baseline and month 6, with grading of pulmonary stenosis defined as: mild \<2, moderate: 2-4; severe \>4
- Secondary Outcome Measures
Name Time Method Functional improvement measured as decreased pulmonary regurgitation (regurgitation classification by transthoracic echocardiogram ) 1 month Improved valve function demonstrated by a decrease in pulmonary regurgitation (PR) to mild or less (≤ 2) by transthoracic echocardiogram (TTE) at month-1
Functional improvement measured as decreased pulmonary regurgitation (regurgitation classification by MRI) month 6 Improved valve function demonstrated by a decrease in pulmonary regurgitation (PR) to mild or less (≤ 2) by MRI at month-6
Safety measured as percentage of subjects experiencing serious adverse events up to third year of follow-up Within the duration of the study of the percentage of patients experiencing the following events is measured:
* Device migration/embolization
* Valvar thrombosis
* Thromboembolism
* Bleeding
* Paravalvar leak
* Endocarditis
* Nonstructural dysfunction
* Explant
* Hemolysis
* Arrhythmias
* all other serious adverse events as defined in protocol section 6.2